摘要
对 47例膀胱移行细胞癌 (BTCC组 )、2 8例膀胱良性肿瘤 (良性组 )及 2 5例健康志愿者 (对照组 )行尿膀胱肿瘤抗原 (BTA)测定及尿脱落细胞学 (VUC)检查。结果 :BTCC组与对照组、良性组的尿 BTA浓度分别为(4.83± 1.81) U/ m l、(1.19± 0 .2 1) U/ ml、(1.3 7± 0 .68) U/ ml。BTCC组尿 BTA浓度与良性组及对照组比较均存在显著差异 (P<0 .0 1)。尿 BTA测定对 BTCC的诊断有较高的敏感性 (85 .1% )和特异性 (88.9% ) ,优于 VU C检查。 BTA浓度与膀胱肿瘤的临床分期和病理分级呈正相关。 BTA与 VUC同时应用可提高 BTCC检出率。认为BTA测定可提高 BTCC早期诊断率。
To investigate the clinical value with the urinary bladder tumor antigen test (BTA) and voiding urinary cytology test (VUC),47 cases with the bladder transitional cell carcinoma(BTCC group),28 cases with the benign tumor of bladder (benign tumor group),and 25 comparison persons(control group ) were collected and tested The results showed that the urine level of BTA in BTCC group is higher than that of benign tumor group and control group respectively(4 83±1 81)U/ml,(1 19±0 21)U/ml and(1 37±0 68)U/ml,P<0 01 The BTA test had higher sensitivity (85 1%) , specificity (88 9%) and the positive correlation in the consistency of voided urine samples between the clinical stages and pathological grade The diagnostic rate in the BTCC was increased by using the BTA test and the VUC These suggest that the BTA have high significance in the filtration, clinical diagnosis, and recurrence of early BTCC
出处
《山东医药》
CAS
北大核心
2003年第3期12-13,共2页
Shandong Medical Journal
基金
山东省临沂市科技发展计划立项课题 (0 1NO0 11110 1)
